The 2026 EAU Guidelines update for nonmuscle-invasive bladder cancer (NMIBC: TaT1 and CIS), covering diagnosis, risk stratification, treatment (including BCG-unresponsive disease and immune checkpoint inhibitors), follow-up, and a new de-intensification strategy — based on a structured review of MEDLINE, EMBASE, and Cochrane Library.
Key updates include: new risk factor and prognostic factor tables for progression in NMIBC subtypes; two new tables on BCG-unresponsive tumor treatment options; a new section on adding immune checkpoint inhibitors to BCG in high- and very high-risk BCG-naïve patients; a new urinary marker follow-up table; and a pragmatic de-intensification strategy section.
This is a guideline summary, not a primary study — no original patient-level data or statistical outcomes are reported. Evidence quality and recommendation strength vary across individual topics within the guidelines.
Clinicians managing NMIBC should integrate the updated BCG-unresponsive treatment pathways and consider immune checkpoint inhibitors added to BCG for high- and very high-risk BCG-naïve patients. Risk stratification remains central — use updated prognostic tables to guide treatment intensity and de-intensification decisions.
